莱博雷生(Lemborexant) - 药物靶点：Orexin receptor_在研适应症：入睡和睡眠障碍，苏醒期谵妄，睡眠_专利_临床

概要

基本信息

药物类型

小分子化药

别名

DAYVIGOTM、LEM、Lemborexant (JAN/USAN/INN)

+ [6]

靶点

Orexin receptor

作用方式

拮抗剂

作用机制

食欲素受体拮抗剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Washington University School of Medicine

Eisai Co., Ltd.Eisai Ltd.

+ [6]

非在研机构

Purdue Pharma LP

权益机构

Eisai Co., Ltd.

Purdue Pharma LP

最高研发阶段批准上市

首次获批日期

加拿大 (2019-09-03),

入睡和睡眠障碍

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C22H20F2N4O2

InChIKeyMUGXRYIUWFITCP-PGRDOPGGSA-N

CAS号1369764-02-2

关联

78

项与莱博雷生相关的临床试验

NCT07384429

/ Not yet recruiting临床4期IIT

Study for the Dual Orexin Receptor Antagonist Lemborexant in Improving Motor-Sleep Comorbidity in Parkinson's Disease

The aim of this study is to explore the effects of the dual orexin receptor antagonist Lemborexant on improving motor and sleep comorbidity in patients with Parkinson's disease. This study will provide clinical evidence for the application of dual orexin receptor antagonists in the treatment of Parkinson's Disease.

开始日期2026-08-19

申办/合作机构

武汉大学中南医院

[+2]

NCT07407400

/ Not yet recruiting临床4期IIT

Lemborexant for Sleep Promotion and Delirium Prevention in Critically Ill Adults: A Combined Feasibility-Pilot, Randomized, Double-Blind, Placebo-Controlled Trial

Sleep disturbance is very common among critically ill patients in the intensive care unit (ICU), particularly in older adults after surgery. Poor sleep in the ICU is associated with important complications, including delirium, longer duration of mechanical ventilation, prolonged hospital stay, and increased mortality. Current non-drug approaches to improve sleep, such as reducing noise and light and clustering nursing care, may provide limited benefit and are often difficult to implement consistently. Safe and effective drug treatments for sleep in critically ill older patients remain limited.
Lemborexant is a dual orexin receptor antagonist that promotes sleep by blocking wake-promoting pathways in the brain. Unlike many traditional sleep medications, lemborexant has minimal effects on breathing and has been shown to be well tolerated in older adults with insomnia. However, its effects on sleep and delirium have not been studied in critically ill patients.
This study is a single-center, randomized, double-blind, placebo-controlled feasibility and pilot trial conducted in the surgical intensive care unit of Siriraj Hospital, Bangkok, Thailand. The study will enroll 100 critically ill postoperative patients aged 65 years or older who are expected to remain in the ICU for at least 48 hours. Participants will be randomly assigned to receive either low-dose lemborexant (2.5 mg) or a matching placebo once nightly for three consecutive nights. All participants will also receive standard non-pharmacologic sleep-promoting care used in the ICU.
The main goals of this pilot study are to evaluate the feasibility and safety of administering lemborexant in elderly ICU patients and to explore its potential effects on sleep and delirium. Sleep will be assessed using both subjective questionnaires completed each morning and objective wrist-worn actigraphy to measure sleep duration and sleep stages. Delirium will be assessed twice daily using a standardized delirium screening tool for up to seven days or until ICU discharge. Additional outcomes include medication adherence, adverse events, duration of mechanical ventilation, length of ICU and hospital stay, and in-hospital mortality.
The results of this study will provide important preliminary data on the feasibility, safety, and potential benefits of lemborexant in critically ill older adults and will help inform the design of future larger clinical trials aimed at improving sleep and reducing delirium in the ICU.

开始日期2026-04-01

申办/合作机构

Mahidol University

CTR20260539

/ CompletedN/A

莱博雷生片5mg生物等效性试验

主要研究目的以福安药业集团庆余堂制药有限公司生产的莱博雷生片（规格：5mg）为受试制剂（T），按有关生物等效性试验的规定，以エーザイ株式会社持证的莱博雷生片（商品名：DAYVIGO®，规格：5mg）为参比制剂（R）进行生物等效性试验。次要研究目的观察受试制剂与参比制剂莱博雷生片在健康受试者中的安全性。

开始日期2026-03-06

申办/合作机构

福安药业集团庆余堂制药有限公司

100 项与莱博雷生相关的临床结果

登录后查看更多信息

100 项与莱博雷生相关的转化医学

登录后查看更多信息

100 项与莱博雷生相关的专利（医药）

登录后查看更多信息

320

项与莱博雷生相关的文献（医药）

2026-12-01·Sleep medicine: X

Effect of lemborexant on insomnia severity, morning alertness, and cognition in participants with insomnia disorder and mild obstructive sleep apnea

Article

作者: Lowe, Alan ; Gottschalk, Raymond ; Ramos, Barbara ; Kumar, Dinesh ; Cheng, Jocelyn Y ; Moline, Margaret

Objective:

To examine the effect of lemborexant (LEM) on insomnia severity, morning alertness, and cognition in participants with COMISA (comorbid insomnia and obstructive sleep apnea [OSA]).

Methods:

This post hoc analysis of study E2006-G000-304 (NCT02783729), a phase 3, randomized, double-blind, 1-month, parallel-group study of LEM 5 mg (LEM5), LEM 10 mg (LEM10), zolpidem tartrate extended-release 6.25 mg (ZOL), and placebo (PBO) included participants with insomnia and mild OSA (≥5 to <15 events/h sleep). Disease severity (assessed via Insomnia Severity Index [ISI]), cognition, and morning alertness were examined.

Results:

This analysis included 410 participants (LEM5, n = 114; LEM10, n = 105; ZOL, n = 113; PBO, n = 78) with COMISA. Mean (SD) changes from baseline in ISI total scores were lower (improved) with LEM5 (-7.1 [5.3]), LEM10 (-7.7 [5.6]), and ZOL (-8.7 [6.7]) versus PBO (-5.7 [5.9]) at Day 31, with LEM10 and ZOL reaching statistical significance (LEM5 vs PBO: P = 0.1100; LEM10 vs PBO: P = 0.0278; ZOL vs PBO: P = 0.0011). LEM did not significantly impact next-morning cognitive functioning and alertness. ZOL negatively impacted power of attention and quality of memory cognitive domains at Days 2/3 and speed of memory retrieval at Days 30/31 versus PBO.

Conclusion:

LEM reduced insomnia severity without significantly impacting next-morning cognitive functioning and alertness in patients with mild untreated OSA.

2026-12-01·Sleep medicine: X

Effects of lemborexant on sleep quality and its association with morning alertness: Post hoc analysis of two phase 3 trials

Article

作者: Cheng, Jocelyn Y ; Koebis, Michinori ; Khullar, Atul ; Kumar, Dinesh ; Kogo, Yuki ; Moline, Margaret ; Kuriyama, Kenichi ; Inabe, Kanako ; Yoshiike, Takuya ; Pinner, Kate ; Suzuki, Masahiro

Study objectives:

This analysis was conducted to determine whether lemborexant (LEM) treatment affects ratings of patient-reported sleep quality and to identify subjective and objective parameters associated with improved subjective sleep quality.

Methods:

This was a post hoc analysis of two global phase 3 trials (Study 303: 12-month, randomized, double-blind, placebo-controlled trial; Study 304: 1-month, randomized, double-blind, placebo-controlled, active-comparator trial) of LEM for patients with insomnia. A 9-point Likert scale (higher numbers indicating better quality) was used to assess subjective sleep quality (sQual). Subjective and objective sleep parameters were assessed by electronic sleep diaries and polysomnography, respectively. Spearman's rank correlation analysis and stepwise regression analysis were performed to explore the associations between sleep parameters and sQual.

Results:

The analyses included 949 patients from Study 303 and 743 patients from Study 304. LEM showed significantly larger increases from baseline in sQual than placebo in both studies (least square mean change: placebo 0.89, LEM5 1.17 (p < 0.05), LEM10 1.21 (p < 0.05) at Month 6 in Study 303, and placebo 0.93, LEM5 1.46 (p < 0.001), LEM10 1.35 (p < 0.05) at Month 1 in Study 304). Of subjective sleep parameters, changes in morning alertness showed the strongest association with changes in sQual. The changes in subjective total sleep time and wake after sleep onset were moderately correlated with sQual positively and negatively, respectively. These findings were further confirmed using stepwise regression analyses.

Conclusions:

LEM improved ratings of sQual more than placebo. To improve self-reported sleep quality, lemborexant treatment should focus on improving morning alertness.

Clinical trial registration:

Study 303 (ClinicalTrials.gov NCT02952820): Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2). https://clinicaltrials.gov/study/NCT02952820, Study 304 (ClinicalTrials.gov NCT02783729): Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older with Insomnia Disorder (SUNRISE 1). https://clinicaltrials.gov/study/NCT02783729.

2026-06-01·JOURNAL OF PSYCHIATRIC RESEARCH

Acceptability of suvorexant versus lemborexant: An inverse probability of treatment weighting analysis

Article

作者: Sakuma, Kenji ; Saito, Takeo ; Araki, Haruna ; Hatano, Masakazu ; Kishi, Taro ; Yamada, Shigeki ; Hatano, Kota

We conducted a retrospective study using medical records from Fujita Health University Hospital to evaluate the treatment discontinuation rates of suvorexant and lemborexant in patients with insomnia and to clarify differences in treatment acceptability. This study included patients newly prescribed suvorexant or lemborexant in the Department of Psychiatry between July 2020 and December 2022. The primary endpoint of the study was the discontinuation rate of suvorexant and lemborexant at 4 weeks. Discontinuation due to adverse events and lack of efficacy were assessed as secondary outcomes. The medical records of 1404 patients who were initiated on a dual orexin receptor antagonist during the study period were reviewed, and 1091 patients were included in the final analysis (suvorexant, 323; lemborexant, 768). We estimated the average treatment effect using the inverse probability of treatment weighting based on the propensity score. Discontinuation rates due to all-cause or adverse events did not differ significantly between the two drugs. However, the discontinuation rate due to lack of efficacy was significantly lower for lemborexant (4.9%; 38/768) compared to suvorexant (7.1%; 23/323), with an odds ratio of 0.63 (95% confidence interval, 0.48-0.83). This exploratory finding suggests a potential difference in treatment acceptability associated with efficacy between suvorexant and lemborexant in routine clinical practice, warranting further investigation.

215

项与莱博雷生相关的新闻（医药）

2026-06-18

·摩熵医药

扬子江第5款1.1类新药来袭，抢滩2700亿中药市场！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 6月17日，CDE官网公示，扬子江药业提交的中药1.1类新药ZYY-768颗粒获批临床，拟用于非糜烂性反流病脾虚湿热证。摩熵医药数据显示，这是扬子江药业第5款获批临床的中药1.1类新药。截图来源：CDE官网 ZYY-768颗粒2026年4月1日首次申请临床，6月17日批准临床，全程仅用两个半月。市场层面，摩熵医药全终端医院数据库显示，2025年中成药在全国院内市场的销售额近2700亿元；2026年Q1中成药在全国院内市场的销售额超570亿元。截图来源：摩熵医药全终端医院市场销售数据库（查数据.找摩熵）中药创新方面，扬子江已形成梯队化布局。截至目前，公司已有ZGZHR-061颗粒、ZYY-742凝胶、清肠温中片、芩翘咽舒颗粒、ZYY-768颗粒共计5款中药1.1类新药获批临床，覆盖多个治疗领域，中药原创研发成果持续落地。截图来源：摩熵医药中国药品审评数据库（查数据.找摩熵）整体创新管线方面，扬子江已有4款1类新药成功获批上市。其中，法赞雷生片于2026年5月21日正式获批，是企业近期创新管线的核心成果。在此之前，卫材的莱博雷生（2025年5月）与Idorsia/先声药业的达利雷生已先后在中国获批，国内DORA市场由进口品种主导。法赞雷生片作为国内首款国产DORA类失眠治疗药物，该药打破了外资长期垄断的市场格局，实现国产DORA类药物零的突破，也是国内失眠精准治疗领域的重要里程碑。截图来源：摩熵医药中国药品审评数据库（查数据.找摩熵）从临床价值看，DORA类药物通过阻断食欲素与其受体结合来抑制过度活跃的觉醒通路，区别于传统镇静类失眠药物，能够在不改变睡眠结构的前提下帮助患者入睡和保持睡眠，且无成瘾性、可长期使用。全球失眠确诊人数超过8.5亿，仅中国就有3亿多人；2025年全球失眠药物市场约29.5亿美元，预计2034年将达46.2亿美元。法赞雷生片Ⅲ期临床共纳入1034例患者，结果显示快速起效且安全性良好。该药的上市，填补了国内失眠精准治疗领域的国产空白，也为数千万失眠患者提供了新的治疗选择。 END 本文为原创文章，转载请留言获取授权点击阅读原文，申请摩熵医药企业版免费试用！

2026-06-17

·VIP说

2026年上市新药最密集的靶点，是怎么零封失眠的？

一个微小的海岛国家，一支初出茅庐的球队，竟然将夺冠大热门、欧洲杯冠军西班牙队逼成了0-0平！面对西班牙队，40岁的佛得角门将沃齐尼亚化身叹息之墙，完成了7次扑救与10次长传，带领佛得角队以弱克强，这就是足球的魅力！看完这场比赛之后，我觉得久久不能平静，过了很久都没有睡着觉，不知道踢完球当天晚上西班牙队的球员能睡着吗…… 好吧，我们睡不着觉，还真跟我大脑深处的一个“门将”有关…… 大脑里还真有拦截睡意的门将在我们的大脑深处，有一类叫做食欲素（Orexin）的神经递质，虽然名叫食欲素，但它和食欲基本没有关联，主要负责维持清醒。[1] 它会在人紧张、焦虑的状态下高度活跃，确保人体能时刻保持清醒状态，能够充满活力地工作、生活。如果只是因为短时间内的紧张兴奋而偶尔无法入睡还好，但对于平时生活压力较大的失眠患者而言，过度活跃的食欲素系统也是慢性失眠的主要诱因之一[2，3]，这个时候强力门将非但不能再帮助你保持良好的生活状态，反而成了踢乌龙球，影响日常生活的糟糕家伙。吹响完赛的哨声所以充分发挥食欲素系统的战术水平，是失眠药物研发的一个重要方向，不久之前，中国首款双重食欲素受体拮抗剂莱博雷生上市，通过部分阻断食欲素受体与食欲素的结合，调低过度亢奋的清醒信号，当“保持清醒”的指令被中断，大脑终于意识到：“哦，原来一天的比赛真的结束了。” 从而积攒了一天的“睡意”终于能够顺理成章地推射空门，让人体更为自然地进入睡眠状态。随着夜间的药物代谢，与清晨食欲素水平的自然升高，食欲素系统重新发挥作用，让人体自然回到清醒状态，与传统的失眠治疗药物相比，更不容易引起次日注意力涣散、昏沉[4,5]。世界杯期间，即使难免熬夜看球，也别让大脑里的“门将”被迫连续加班。比赛再精彩，也要记得适时吹响作息的终场哨。合理安排睡眠时间，科学调节作息，第二天才能精力充沛地回归工作与生活。看好球，更要睡好觉。参考文献： 1. Sakurai T, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573-585. 2. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011;51:243-266. 3. Muehlan C, et al. The orexin story and orexin receptor antagonists for the treatment of insomnia. J Sleep Res. 2023;32(6):e13902. 4. Rosenberg R, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254. 5. Kärppä M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43(9):zsaa123.

临床研究临床结果

2026-06-17

·健识局

618越熬越睡不着？90%的电商人忽略了这个"清醒开关"

618大促倒计时，凌晨一点半。运营小张改完最后一版活动页面，瘫在床上，脑子却像装了马达——今天的GMV、明天的玩法、售后差评……越想越清醒，越累越睡不着。翻个身刷朋友圈：同行吐槽、老板战报、竞品促销截图……一片灯火通明。这哪是大促？分明是一场"睡眠大逃杀"。你是不是也这样？白天拼命冲业绩，晚上拼命睡不着。心里想的是过了618好好补觉，身体却在说：今晚谁都别想睡。今天不聊KPI，聊聊——为什么你越累，反而越睡不着？很多人觉得，失眠，就是压力太大、想得太多。这是片面的认知。从睡眠医学角度来看，这类“越累越清醒”的失眠，核心根源并非单纯的心理压力，而是身体出现了过度觉醒状态。想要摆脱失眠，首先就要读懂这场由身体内部引发的“觉醒危机”。食欲素+双重受体，掌控你的清醒与睡眠很多人失眠，根源都和一种名为食欲素的物质息息相关。单从名字来看，大家很容易误以为它负责调控食欲，这其实是普遍的认知误区。食欲素也被称作下丘脑泌素，它真正的核心作用，是掌管人体睡眠——觉醒节律，是大脑与生俱来的“清醒开关”[2、3]。食欲素日间正常分泌可维持机体警觉，夜间分泌回落以保障睡眠。熬夜加班、精神压力大、作息失调会扰乱其分泌规律，造成夜间活性过高，令大脑持续兴奋，是职场人群劳累后失眠、眠浅多梦的核心诱因[4、5]。食欲素想要发挥唤醒作用，必须依托大脑内OX1R、OX2R两种核心受体，二者共同影响着我们的睡眠状态。其中，OX1R更多参与应激、奖赏和警觉反应等相关神经环路。当压力增大、精神紧绷或反复担忧时，OX1R相关通路可能被进一步调动，使大脑更容易处于“警觉、紧张、停不下来”的状态。 OX2R则与维持清醒状态、稳定睡眠-觉醒转换关系更为密切。它参与帮助大脑保持白天清醒，同时影响夜间从清醒向睡眠过渡的稳定性。当OX2R相关觉醒信号持续活跃时，人即使身体已经疲惫，大脑也可能仍然难以关机，表现为入睡困难、夜间易醒或醒后难以再次入睡。因此，在长期熬夜、高压工作、情绪紧绷等情况下，食欲素系统可能持续参与大脑的过度觉醒状态：一方面，OX1R相关通路可能让紧张、担忧和杂念更加突出；另一方面，OX2R相关通路可能让清醒状态难以平稳切换到睡眠状态。二者共同作用，容易形成“越累越清醒、越想睡越睡不着”的失眠体验。从“强行睡得着”到“自然睡得好”：DORAs药物重新定义职场睡眠面对失眠，传统安眠药和以莱博雷生为代表的DORAs（双重食欲素受体拮抗剂），代表了两种完全不同的助眠思路，也拉开了“单纯睡得着”和“真正睡得好”的差距。传统安眠药通过增强抑制性神经递质、全面压制中枢神经，相当于直接“砸掉”大脑里的清醒闹钟强制使人入睡。但这种方法会打乱人体正常睡眠结构，还易造成次日头昏、反应变慢、注意力不足，影响日常工作；长期服用还可能产生药物依赖与戒断反应。而莱博雷生这类药物则彻底革新了助眠逻辑。它不会无差别麻痹神经，而是精准靶向OX1R、OX2R两大受体，阻断食欲素的唤醒信号，相当于轻轻按下闹钟的响铃键，顺应人体原本的生理节律，引导大脑自然进入睡眠[6]。作为DORAs类药物中的代表药物之一，莱博雷生是典型的双重食欲素受体拮抗剂，能够同时拮抗OX1R、OX2R两大核心受体，从情绪杂念、睡眠节律两大维度切断失眠诱因，实现双通路同步干预。其中，莱博雷生对OX2R核心节律受体的结合效果尤为突出，能够更高效地阻断食欲素对睡眠节律的干扰，针对性解决因OX2R过度激活引发的入睡难、睡眠维持差等问题，对职场人高发的过度觉醒型失眠改善效果更精准[6]。莱博雷生：快结合、快解离，次日清醒不昏沉莱博雷生也是国内首个获批的双重食欲素受体拮抗剂，在同类DORAs药物中，凭借独特的药理特性脱颖而出，相较于其他同类型雷生类药物，它的核心优势集中在受体结合能力与代谢特性上。依托“快结合、快解离”的受体结合动力学特性，实现快速结合受体发挥助眠作用，帮助疲惫的职场人迅速进入睡眠；待到次日清晨，药物又会快速解离代谢，几乎无嗜睡、乏力等残留效应[6-8]。写在最后好睡眠不是工作的"奢侈品"，而是高效状态的"燃料"。愿每一个在深夜奋斗的你，业绩漂亮，睡得也漂亮。参考文献 [1] 傅晗昕, 张芯, 胡霖霖. 失眠过度觉醒状态的中西医研究进展[J]. 中华全科医学, 2025, 23(7): 1098-1102. doi: 10.16766/j.cnki.issn.1674-4152.004073 [2] 食欲素的发现与临床应用：从基础研究到转化医学的成功范例[J]. 中国临床药理学与治疗学,2025,30(11):1441-1442 [3] VillanoI,LaMarraM,DiMaioG,MondaV,ChieffiS,GuatteoE,MessinaG,MoscatelliF,MondaM,MessinaA.PhysiologicalRoleofOrexinergicSystemforHealth.IntJEnvironResPublicHealth.2022Jul8;19(14):8353. [4] 超越睡眠觉醒调控：食欲素调控认知与情绪功能研究进展[J]. 中国临床药理学与治疗学,2025,30(11):1453-1466 [5] SarginD.Theroleoftheorexinsysteminstressresponse.Neuropharmacology.2019Aug;154:68-78. [6] 中国睡眠研究会，广东省医师协会睡眠医学专业委员会，广东省医院协会医院药事管理专业委员会，等。莱博雷生临床应用中国专家共识[J].中国全科医学，2026,29(05):545-558. [7]MiWF,WenD,XuL,etal.APhase3,Multicenter,Double-Blind,Randomized,Placebo-ControlledClinicalTrialofLemborexantinAdultsWithInsomniaDisorder[J].SleepMedicine,2025,139:108722. [8]Beuckmann,C.T.,Suzuki,M.,Ueno,T.,Nagaoka,K.,Arai,T.,&Higashiyama,H.(2017).InVitroandInSilicoCharacterizationofLemborexant(E2006),aNovelDualOrexinReceptorAntagonist.TheJournalofpharmacologyandexperimentaltherapeutics,362(2),287–295. AI医疗的全场景落地路径，京东健康走通了诺华降价53%背水一战，IgA肾病市场大乱斗康方生物银屑病1类新药获批上市

100 项与莱博雷生相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11022	莱博雷生	N05C	DB11951

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
入睡和睡眠障碍	加拿大	Eisai Co., Ltd.	2019-09-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
苏醒期谵妄	临床2期	加拿大	Eisai, Inc.	2025-05-01
睡眠	临床2期	加拿大	Eisai, Inc.	2025-05-01
阻塞性睡眠呼吸暂停综合征	临床2期	泰国	University of Chulalongkorn	2023-02-01
阿尔茨海默症	临床2期	美国	Eisai, Inc.	2016-12-20
阿尔茨海默症	临床2期	美国	Purdue Pharma LP	2016-12-20
阿尔茨海默症	临床2期	日本	Purdue Pharma LP	2016-12-20
阿尔茨海默症	临床2期	日本	Eisai, Inc.	2016-12-20
阿尔茨海默症	临床2期	英国	Purdue Pharma LP	2016-12-20
阿尔茨海默症	临床2期	英国	Eisai, Inc.	2016-12-20
日夜节律睡眠障碍	临床2期	美国	Eisai, Inc.	2016-12-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02783729 (E2006-G000-304, AAN 12026 \| AAN 22026 \| AAN 32026 \| AAN 42026 \| AAN 52026 \| AAN 62026)	临床3期	入睡和睡眠障碍	1,763	Lemborexant 5mg	構齋齋製壓繭觸淵齋鹽(餘淵衊簾壓淵網廠窪鹽) = 襯鏇壓網積鬱積鏇選齋壓獵衊鑰遞鏇鑰齋壓顧 (製簾獵鏇鬱襯製繭齋鏇 )	积极	2026-04-25
				Lemborexant 10mg	構齋齋製壓繭觸淵齋鹽(餘淵衊簾壓淵網廠窪鹽) = 壓艱築鏇選鏇鹽壓膚醖壓獵衊鑰遞鏇鑰齋壓顧 (製簾獵鏇鬱襯製繭齋鏇 )
NCT05458609 (CTgov)	临床3期	酒精使用障碍	8	Lemborexant 10 mg+Naltrexone (Lemborexant Plus Naltrexone)	構獵憲壓膚鏇網淵廠鹽(繭築構願築壓鹹製製膚) = 襯獵襯獵鏇餘餘選願鏇蓋築廠鹽選糧積願壓齋 (鑰蓋製製築艱壓壓範淵, 16.77) 更多	-	2026-03-24
				Naltrexone (Placebo Plus Naltrexone)	構獵憲壓膚鏇網淵廠鹽(繭築構願築壓鹹製製膚) = 淵窪夢淵顧衊蓋艱齋鑰蓋築廠鹽選糧積願壓齋 (鑰蓋製製築艱壓壓範淵, 21.94) 更多
NCT05344443 (CTgov)	临床4期	日夜节律睡眠障碍	29	Lemborexant (Active Treatment)	顧齋顧鏇繭襯鑰鹹窪繭(積壓鑰鹹衊憲餘築觸獵) = 鬱襯壓築網遞範衊鹹網艱壓淵願鑰鏇淵衊衊鑰 (蓋遞鏇鬱簾蓋遞艱夢壓, 22.0) 更多	-	2026-02-04
				Placebo (Placebo Treatment)	顧齋顧鏇繭襯鑰鹹窪繭(積壓鑰鹹衊憲餘築觸獵) = 製繭製願淵製鑰壓鹽觸艱壓淵願鑰鏇淵衊衊鑰 (蓋遞鏇鬱簾蓋遞艱夢壓, 22.4) 更多
NCT06981195 (Pubmed \| BMJ Open)	临床2期	入睡和睡眠障碍	100	Lemborexant	廠憲醖繭膚構廠築製鬱(膚鹽蓋鏇膚窪積鏇餘網) = 壓窪醖蓋蓋蓋艱鹹鏇淵範壓壓範觸齋顧壓淵鹹 (繭襯鬱醖鏇鏇範壓窪廠 ) 更多	积极	2025-10-01
NCT05594589 (E2006-J082-204, CTgov)	临床2期	入睡和睡眠障碍	65	lemborexant+placebo (Placebo)	淵獵壓夢積願鑰獵鹹窪(鏇窪獵製網選鏇築憲獵) = 願衊繭憲衊網鹽衊糧範選糧壓築醖鹹鑰膚構鏇 (繭淵襯醖簾鹽膚繭襯醖, 59.006) 更多	-	2025-07-03
				Lemborexant (Lemborexant 5 mg)	淵獵壓夢積願鑰獵鹹窪(鏇窪獵製網選鏇築憲獵) = 遞鏇鏇醖築艱醖築襯鬱選糧壓築醖鹹鑰膚構鏇 (繭淵襯醖簾鹽膚繭襯醖, 55.263) 更多
NCT04549168 (CTgov)	临床3期	入睡和睡眠障碍	194	lemborexant+placebo (Randomization Phase: Placebo)	簾鑰構醖遞遞鬱觸廠鏇(衊繭鬱構積構製襯築夢) = 醖艱壓鬱遞觸網鏇鹽願膚窪構蓋鹽築範願製艱 (醖壓廠願醖構鹹簾鬱壓, 42.809) 更多	-	2024-12-20
				Lemborexant (Randomization Phase: Lemborexant 10 mg)	簾鑰構醖遞遞鬱觸廠鏇(衊繭鬱構積構製襯築夢) = 鬱糧鏇鏇壓餘夢糧餘衊膚窪構蓋鹽築範願製艱 (醖壓廠願醖構鹹簾鬱壓, 46.147) 更多
NCT04818086 (CTgov)	临床1/2期	阿片滥用 \| 药物相互作用	18	Lemborexant+Buprenorphine-naloxone (Lemborexant Arm)	醖繭構糧醖觸鹹鹹範膚(網鹽齋襯衊憲襯淵遞遞) = 觸製積觸繭鏇衊窪憲憲餘顧鬱壓鬱選獵醖廠顧 (顧簾蓋壓鬱壓鹽簾淵鬱, .94) 更多	-	2024-11-13
				Placebo+Buprenorphine-naloxone (Placebo Arm)	醖繭構糧醖觸鹹鹹範膚(網鹽齋襯衊憲襯淵遞遞) = 糧觸顧壓鑰膚衊襯遞鹽餘顧鬱壓鬱選獵醖廠顧 (顧簾蓋壓鬱壓鹽簾淵鬱, .82) 更多
AAN2024	N/A	入睡和睡眠障碍 \| 睡眠-觉醒节律障碍	-	Lemborexant 5 mg	艱餘餘繭淵鏇築憲壓鑰(餘鹹願獵築築獵構膚繭) = LEM was well tolerated with most treatment-emergent adverse events mild/moderate in severity 顧積繭製餘廠遞觸築觸 (襯齋醖製遞壓蓋夢膚蓋 )	-	2024-04-09
				Lemborexant 10 mg
NCT04890561 (E2006-A001-010, Pubmed \| Br J Clin Pharmacol)	临床1期	-	8	Lemborexant 10mg	鏇憲鏇製鹹壓鹽製範夢(構鹹觸憲蓋選齋壓襯窪) = Mild treatment‐emergent adverse events were reported in 4 subjects; these all resolved by end of study 鹽膚觸範構網繭蓋鹹繭 (衊衊築淵鏇醖繭簾夢網 )	积极	2024-01-01
NCT04647383 (E2006-A001-113, Pubmed \| J Clin Sleep Med)	临床1期	阻塞性睡眠呼吸暂停综合征	33	Lemborexant 10 mg	艱憲衊構鹹選鑰窪鬱齋(願範積範構積積網鏇鏇) = 製醖簾願鑰艱積窪選醖遞選鏇製膚襯艱衊範壓 (蓋淵網願醖醖蓋夢衊衊 )	积极	2024-01-01
				Placebo	艱憲衊構鹹選鑰窪鬱齋(願範積範構積積網鏇鏇) = 願遞構鏇顧齋鹽範蓋鹽遞選鏇製膚襯艱衊範壓 (蓋淵網願醖醖蓋夢衊衊 )